Ruxience package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Active ingredient: RituximabCancer medications

Ruxience (Rituximab)

Other Brands:Rituxan

Rituxan

Rituximab

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:

Ruxience

Rituximab

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Ruxience (rituximab) is a cd20-directed cytolytic antibody listed in our Cancer medications directory and prescribed for specified inflammatory joint conditions and specified blood or lymphatic cancers (1.1) (2.1). administered via the intravenous route, Ruxience is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Ruxience is a medication containing the active pharmaceutical ingredient rituximab, classified pharmacologically as a cd20-directed cytolytic antibody (2.1). It is clinically indicated for the management of specified inflammatory joint conditions and specified blood or lymphatic cancers as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Cancer medications section of our catalogue, patients and prescribers frequently review Ruxience alongside related therapies such as Rituxan (Rituximab), Truxima (Rituximab-abbs), Avastin (Bevacizumab), and Besponsa (Inotuzumab ozogamicin).

Official Indications and Usage

Ruxience is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (cvp) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (chop) or other anthracycline-based chemotherapy regimens. (1.1)

Mechanism of Action and Pharmacology

Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (adcc). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. (1.1)

What is Inflammatory arthritis?

Inflammatory arthritis can cause persistent joint inflammation and damage. Disease-modifying medicines and symptom medicines serve different roles. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Inflammatory arthritis condition guide for appointment questions and related therapies (2.1).

What are Blood and lymphatic cancers?

Leukemia, lymphoma, and multiple myeloma are different cancers involving blood-forming or immune cells. Their medicine regimens are diagnosis-specific. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Blood and lymphatic cancers condition guide for appointment questions and related therapies (2.1).

Ordering Ruxience from Canada for U.S. Delivery

U.S. patients can order Ruxience (Rituximab) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Ruxience
Chemical / Generic Name Rituximab
Pharmacological Class CD20-directed Cytolytic Antibody
Therapeutic Category Cancer medications
Same-Ingredient Catalogue Entries Rituxan (Rituximab)
Molecular Weight 145 g/mol (2.1)
Elimination Half-Life ~22 days (1.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NLM MedlinePlus
Routes of Administration Intravenous
Dosage Forms & Strengths Injection: Rituxan is a colorless, clear solution for intravenous infusion: 100 mg/10 mL (10 mg/mL) in a single-dose vial 500 mg/50 mL (10 mg/mL) in a
Primary Indications Specified Inflammatory Joint Conditions And Specified Blood Or Lymphatic Cancers
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
FDA UNII Identifier 4F4X42SYQ6
NLM RxNorm Concept ID (RxCUI) 1657862, 1657864, 1657867, 1657868
FDA Application License BLA103705
Official DailyMed SetID b172773b-3905-4a1c-ad95-bab4b6126563
Catalogue Index Links Letter R Index · All Medications · All Categories

Directions

Dosage and Administration Overview

Administer only as an intravenous infusion. Do not administer as an intravenous push or bolus. Rituxan should only be administered by a healthcare professional with appropriate medical support to manage severe infusion-related reactions that can be fatal if they occur. The dose for adult and pediatric B-cell NHL is 375 mg/m 2. The dose for CLL is 375 mg/m 2 in the first cycle and 500 mg/m 2 in cycles 2-6, in combination with FC, administered every 28 days. (1.1)

Presentations and Strengths

Injection: Rituxan is a colorless, clear solution for intravenous infusion: 100 mg/10 mL (10 mg/mL) in a single-dose vial 500 mg/50 mL (10 mg/mL) in a single-dose vial Injection: 100 mg/10 mL (10 mg/mL) and 500 mg/50 mL (10 mg/mL) solution in single-dose vials. (1.1)

Administration Guidance

Administer Ruxience by injection or infusion (Intravenous) strictly according to your prescriber’s individualized dosing schedule (1.1). Always verify the concentration, vial or pen presentation, and dose markings prior to administration, rotate injection sites when self-injecting subcutaneously, and never share injection pens, needles, or syringes between patients.

Missed Dose Guidance

If you miss a scheduled dose of Ruxience, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Ruxience is rituximab (2.1). Other catalogue entries containing rituximab include Rituxan (Rituximab).

Excipients and Formulation Carriers

Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).

Cautions and important safety information

Boxed Warning

Warning: fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy Fatal infusion-related reactions within 24 hours of Rituxan infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue Rituxan infusion for severe reactions. Severe mucocutaneous reactions, some with fatal outcomes. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death. (1.1)

Contraindications

None. (1.1)

Key Clinical Precautions

Before starting or continuing Ruxience, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.
  • Gastrointestinal ulceration, bleeding, and perforation: Serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines can occur with or without warning symptoms.
  • Fetal toxicity and pregnancy considerations: This medication may cause fetal harm when administered to a pregnant patient. Discuss pregnancy planning, effective contraception, and safe treatment alternatives with your healthcare provider.
  • Increased susceptibility to infection: Therapies that modulate immune or metabolic pathways can increase the risk of bacterial, mycotic (fungal), viral, or opportunistic infections. Report fever, persistent cough, painful urination, or localized infection promptly.
  • Malignancy monitoring: Follow age-appropriate and treatment-specific screening recommendations discussed with your prescribing specialist.
  • Hepatic (liver) effects: Elevations in liver enzymes or rare cases of severe hepatic injury have been reported. Baseline and periodic liver function tests may be recommended; seek medical evaluation for jaundice, dark urine, or persistent right-upper-abdominal pain.

Pregnancy, Lactation, and Special Populations

Based on human data, Rituxan can cause adverse developmental outcomes including B-cell lymphocytopenia in infants exposed to Rituxan in-utero. In animal reproduction studies, intravenous administration of rituximab to pregnant cynomolgus monkeys during the period of organogenesis caused lymphoid B-cell depletion in the newborn offspring at doses resulting in 80% of the exposure (based on AUC) of those achieved following a dose of 2 grams in humans. Advise pregnant women of the risk to a fetus. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. (1.1)

Interactions

Official Drug Interaction Overview

Formal drug interaction studies have not been performed with Rituxan. In patients with CLL, Rituxan did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin. (1.1)

Important Interaction Categories

Concomitant use of Ruxience with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Methotrexate: Concomitant use may reduce renal tubular elimination of methotrexate, increasing systemic methotrexate exposure and the risk of hematologic, hepatic, or renal toxicity.

Side effects

Like all medications, Ruxience can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; eating smaller, lower-fat meals and avoiding lying down immediately after eating may help reduce nausea.
  • Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
  • Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
  • Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.

Clinical Trial and Postmarketing Adverse Reactions

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Infusion-related reactions Severe mucocutaneous reactions Hepatitis B reactivation with fulminant hepatitis Progressive multifocal leukoencephalopathy Tumor lysis syndrome Infections Cardiovascular adverse reactions Renal toxicity Bowel obstruction and perforation Most common adverse reactions in clinical trials were: NHL (greater than or equal to 25%): infusion-related reactions, fever, lymphopenia, chills, infection, and asthenia. Pediatric B-NHL/B-AL with chemotherapy (Grade 3 or higher greater than 15%): febrile neutropenia, stomatitis, enteritis, sepsis, alanine aminotransferase increased and hypokalemia. CLL (greater than or equal to 25%): infusion-related reactions and neutropenia. (1.1)

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Store Rituxan vials refrigerated at 2°C to 8°C (36°F to 46°F). Rituxan vials should be protected from direct sunlight. Do not freeze or shake. (1.1)

Store Ruxience in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

Frequently Asked Questions About Ruxience

What is Ruxience and what active ingredient does it contain?

Ruxience is a cd20-directed cytolytic antibody containing the active pharmaceutical ingredient rituximab. It is supplied for intravenous administration and requires a valid prescription where applicable.

How does Ruxience work in the body?

Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (adcc).

What conditions is Ruxience prescribed to treat?

Ruxience is primarily indicated for specified inflammatory joint conditions and specified blood or lymphatic cancers. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Ruxience?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Ruxience is administered via the intravenous route. Administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Ruxience?

Commonly reported side effects of Ruxience include feeling sick, vomiting, loose stools, headache, dizziness, and abdominal pain. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Ruxience?

Important interaction categories for Ruxience include methotrexate. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Ruxience be used during pregnancy or breastfeeding?

Official prescribing information highlights pregnancy-related precautions for Ruxience. Inform your healthcare provider immediately if you are pregnant, planning to become pregnant, or breastfeeding so safe treatment options can be evaluated.

Do I need a prescription to buy Ruxience online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Ruxience (Rituximab) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Ruxience have a generic equivalent (Rituximab) at a Canada pharmacy?

Currently, Ruxience (Rituximab) is dispensed in our catalogue as a brand-name formulation. Check our Rituximab active ingredient hub for updates as licensed generic presentations become available.

How is Ruxience shipped to U.S. residents, and how much does shipping cost?

Ruxience ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Ruxience prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Ruxience prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Ruxience (Rituximab) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Rituxan. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) MedlinePlus Medical Encyclopedia: Rheumatoid Arthritis. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  3. (3.1) MedlinePlus Medical Encyclopedia: Leukemia. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  4. (4.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help